Use of mutagenesis to probe IGF-binding protein structure/function relationships

Endocrine Reviews

Volumn 22, Issue 6, 2001, Pages 800-817

  Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; MUTANT PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

AMINO ACID SEQUENCE; CORRELATION ANALYSIS; HORMONE ACTION; HUMAN; HYDROPHOBICITY; MUTAGENESIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; SYNTHESIS;

EID: 0035719951     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.22.6.0449     Document Type: Review

References (152)

1. Nonsuppressible insulin-like activity of human serum. II. Biological properties of plasma extracts with nonsuppressible insulin-like activity
2. Non-suppressible insulin-like activity in human serum. I. Physicochemical properties, extraction and partial purification
3. Binding of nonsuppressible insulin-like activity to human serum: Evidence for a carrier protein
4. Isolation of a somatomedin-binding protein from preterm amniotic fluid. Development of a radioimmunoassay
5. Isolation and characterization of a somatomedin binding protein from mid term human amniotic fluid
6. Purification of a 31000 dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions
7. Insulin like growth factor binding protein from human plasma, purification and characterization
8. Further characterization of growth hormone dependent somatomedin binding proteins produced by rat liver cells in culture
9. Placental protein 12 is a decidual protein that binds somatomedin and has an identical N-terminal amino acid sequence with somatomedin binding protein from amniotic fluid
10. Purification and amino-terminal sequence of an insulin-like growth factor-binding protein secreted by rat liver BRL-3A cells
11. Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins
12. Cloning, characterization and expression of a human insulin-like growth factor binding protein
13. Insulin like growth factor (IGF) binding protein complementary deoxyribonucleic acid form human Hep G2 hepatoma cells: Predicted protein sequence suggests an IGF binding domain different from those of IGF-I and IGF-II receptors
14. Cloning and expression of the GH dependent insulin like growth factor binding protein
15. Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP in rat and human
16. Nucleotide sequence and expression of a cDNA clone encoding a fetal rat binding protein for insulin-like growth factors
17. Insulin like growth factors and their binding proteins: Biologic actions
18. Insulin like growth factor (IGF) binding proteins: Interactions with IGFs and intrinsic bioactivity
19. Role of insulin like growth factors and their binding proteins in growth control and carcinogenesis
20. Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs
21. Binding of mutants of human insulin-like growth factor-II to insulin-like growth factor binding proteins 1-6
22. Carboxy truncated insulin like-growth factor binding protein-5 stimulates mitogenesis in osteoblast like cells
23. Isolation of a biologically active fragment from the carboxy terminus of the fetal rat binding protein for fetal rat binding protein for insulin-like growth factors
24. A 3-dimensional model for insulin-like growth factor binding proteins (IGFBPs): Supporting evidence using the structural determinants of IGF binding site on IGFBP-3
25. An insulin-like growth factor binding protein enhances the biologic response to IGF-I
26. Insulin like growth factor binding protein-1 inhibits binding of IGF-I on fetal skin fibroblasts but stimulates their DNA synthesis
27. Effect of recombinant IGF binding protein-1 on primary cultures of human keratinocytes and fibroblasts: Selective enhancement of IGF-I but not IGF-II induced cell proliferation
28. Growth hormone dependent insulin-like growth factor binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in skin fibroblasts
29. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-I and IGF-2 but not des-(1-3)-IGF-I
30. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action
31. Inhibitory effects of insulin-like growth factor binding proteins 1 and 3 on IGF activated glucose consumption in mouse Balb/c3T3 fibroblasts
32. Analysis of serum insulin-like growth factor binding proteins using Western blotting. Use of the method for titration of the binding proteins and competitive binding studies
33. Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity labeling
34. Radioimmunoassay of growth hormone dependent insulin-like growth factor binding protein in human plasma
35. Radioimmunoassay of a 26,000 dalton plasma insulin like growth factor binding protein: Control by nutritional variables
36. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects
37. Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids
38. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF binding proteins
39. Effect of insulin on the insulin-like growth factor system in children with new onset insulin-dependent diabetes mellitus
40. The effects of dexamethasone treatment on amino reactive and bioactive insulin like growth factors (IGF's) and IGF binding proteins in normal volunteers
41. Effects of recombinant IGF-I and GH treatment upon serum IGF binding proteins in calorically restricted adults
42. Circulating levels of insulin-like growth factor-I and -II, and IGF-binding protein-3 in inflammation and after parathyroid hormone infusion
43. Recombinant human insulin-like growth factor binding protein-1 inhibits growth stimulated by IGF-I and growth hormone in hypophysectomized rats
44. Benefit of systemically administered rh IGF-I and rh IGF-I/IGBP-3 on cancellous bone in oophorectomized rats
45. Expression of human insulin-like growth factor-binding protein-3 in transgenic mice
46. Insulin like growth factor binding proteins in maternal serum throughout gestation and in the puerperium
47. Alterations in insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis in transformed osteoblastic cells
48. Porcine aortic smooth muscle cells secrete a serine protease for insulin like growth factor binding protein-2
49. Properties of an insulin like growth factor binding protein 4 protease that is secreted by smooth muscle cells
50. Protease resistant IGFBP-5 inhibits actions of IGF-I on porcine smooth muscle cells
51. (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants
52. Heparin modulates the binding of insulin-like growth factor binding protein-5 to a membrane protein in osteoblast cells
53. IGFBP-3 and IGFBP-5 association with endothelial cells: Role of C-terminal heparin binding domain
54. Extracellular matrix contains insulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I
55. Insulin-like growth factor binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis
56. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes
57. Phosphorylation of insulin-like growth factor binding protein in cell culture and in vivo: Effects on affinity for IGF-I
58. Regulation of insulin-like growth factor (IGF) binding protein-3 phosphorylation by IGF-I
59. Identification of the sites of phosphorylation in insulin-like growth factor binding protein-1: Regulation of its affinity by phosphorylation of serine 101
60. Identification of the major sites of phosphorylation in IGF binding protein-3
61. The role of glycosylation in the action of IGFBP-3
62. Human IGFBP-6 is O-glycosylated
63. Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb
64. Demonstration of receptors for insulin-like growth factor binding protein-3 on HS578T breast cancer cells
65. Insulin-like growth factor binding proteins (IGFBPs) secretion by muscle cells: Effect of cellular differentiation and proliferation
66. Identification of the types of insulin like growth factor binding proteins that are secreted by muscle cells in vitro
67. Bioactivity of a 29-kildalton insulin-like growth factor binding protein-3 fragment present in excess in chronic renal failure serum
68. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin
69. Factors regulating insulin-like growth factor binding-3 protein, processing, and potentiation of insulin-like growth factor action
70. The role of cell surface attachment and proteolysis in insulin-like growth factor (IGF) independent effects of insulin-like growth factor binding protein-3 on epithelial cells
71. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the α5β1 integrin by means of its Arg-Gly-Asp sequence
72. Structure of the IGF-binding domain of the insulin-like growth factor binding protein-5 (IGFBP-5): Implications for IGF and IGF-I receptor interactions
73. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF binding and alter their biologic actions
74. Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain
75. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I
76. Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6
77. Isolation from adult human serum forms of insulin-like growth factor binding proteins and molecular cloning of one of them that is increased by IGF-I administration
78. Proteolytic cleavage of insulin like growth factor binding protein-4 (IGFBP-4)
79. Characterization of truncated insulin-like growth factor binding protein-2 in human milk
80. Mutation in the C-terminal part of insulin-like growth factor binding prorein-1 results in diminished function and loss of binding capacity
81. Binding site and binding properties of binary and ternary complexes of insulin-like growth factor-II, IGF binding protein-3, and acid labile subunit
82. Structure function analysis of the human insulin-like growth factor binding protein-4
83. The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry
84. IGF binding proteins and their functions
85. Insulin-like growth factor II (IGF II). Expression and characterization of truncated IGF II and of two naturally occurring variants
86. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II
87. Structural changes in insulin-like growth factor I mutant proteins affecting binding kinetic rate to IGF binding protein-1 and IGF receptor
88. Insulin-like growth factor binding site of bovine insulin-like growth factor binding protein-2 probed by iodination
89. Alanine scanning mutagenesis binding tyrosine 60 of bovine insulin like growth factor binding protein-2 is a determinant of insulin like growth factor binding
90. Overlap of IGF-and heparin-binding sites in rat IGF-binding protein-5
91. Substitution of specific amino acids in insulin-like growth factor-binding protein-5 alters heparin binding and its change in affinity for IGF-I in response to heparin
92. Structural determinants of ligand and cell surface binding of insulin like growth factor binding protein-3
93. Regulation of serum insulin-like growth factor I (IGF-I) and IGF binding proteins during rat pregnancy
94. Enzymatic evidence of degradation of insulin-like growth factor binding protein in 150 K complex during pregnancy
95. Evidence for a novel insulin-like growth factor (IGF)-dependent protease regulating IGF-binding protein-4 in dermal fibroblasts
96. Matrix metalloproteases degrade insulin like growth factor binding protein-3 in dermal fibroblast cultures
97. Identification of the forms of insulin-like growth factor binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion
98. Regulation of insulin like growth factor binding protein-4 by a specific insulin like growth factor binding protein-4 protease in normal human osteoblast like cells. Implications on human cell physiology
99. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line
100. Intact insulin-like growth factor binding protein-5 (IGFBP-5) associates with bone matrix and the soluble fragments of IGFBP-5 accumulated in culture medium of neonatal mouse calvariae by parathyroid hormone and prostaglandin E2-treatment
101. Characterization of insulin-like growth factor binding protein (IGFBP-4) produced by B104 rat neuronal cell line: Chemical and biologic properties and differential synthesis by sublines
102. Evidence that human bone cells in culture produce insulin-like growth factor binding protein-4 and -5 proteases
103. Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding-protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells
104. Characterization of urinary insulin-like growth factor binding proteins
105. Proteolytic activity is involved in changes in intrafollicular insulin-like growth factor-binding protein levels during growth and atresia of ovine ovarian follicles
106. Proteolysis of insulin-like growth factor binding protein-3 in 150 kilodalton IGFBP complexes by a cation dependent protein activity in adult rat serum promotes the release of IGF-I
107. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin
108. Vitreous and aqueous humors contain a latent proteinase activity that abolishes IGF binding to specific IGF binding proteins
109. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty
110. Insulin-like growth factors (IGFs) and IGF-binding proteins in human skin interstitial fluid
111. Studies on the role of human insulin-like growth factor II (IGF-II) dependent IGF binding protein protease in human osteoblasts using protease resistant IGFBP-4 analogues
112. A protease-resistant form of insulin-like growth factor binding protein-4 (IGFBP-4) inhibits IGF-I actions
113. The insulin-like growth factor)IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A
114. Characterization of the enzymatic specificity of IGF-1 dependent insulin-like growth factor binding protein-4 (IGFBP-4) preotease
115. Evidence that the interaction between insulin-like growth factor (IGF) II and IGF binding protein (IGFBP)-4 is essential for the action of the IGF-II dependent IGFBP-4 protease
116. Characterization and determination of the relative abundance of two types of IGFBP-5 proteases that are secreted by human fibroblasts
117. Insulin-like growth factor binding protein-5 (IGFBP-5) is cleaved by physiologic concentrations of thrombin
118. Inhibition of IGFBP-5 binding to extracellular matrix and IGF-I stimulated DNA synthesis by a peptide fragment of IGFBP-5
119. Binding of insulin-like growth factor binding protein-5 to smooth muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I
120. Identification of the extracellular matrix binding site for insulin like growth factor binding protein-5
121. Comparison studies of IGFBP-5 binding to os-teoblasts and osteoblast-derived extracellular matrix
122. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells
123. Binding of insulin-like growth factor I or II to IGF binding protein-2 enables it to bind to heparin or extracellular matrix
124. Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin
125. Glycosaminoglycans inhibit formation of the 140 kDa insulin like growth factor binding protein complex
126. Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor binding protein-3
127. Insulin-like growth factor (IGF) binding protein-5-(201-218) region regulates hydroxyapatite and IGF-I binding
128. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: Studies of underlying mechanism
129. Insulin-like growth factor-I (IGF-I) and transforming growth factor β-1 release IGF-binding protein-3 from human fibroblasts by different mechanisms
130. Insulin-like growth factor binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor
131. High molecular weight insulin-like growth factor binding protein complex: Purification and properties of the acid-labile subunit from human serum
132. Insulin-like growth factor (IGF) binding protein-5 forms an alternative ternary complex with IGFs and the acid labile subunit
133. A central domain binding site in insulin-like growth factor binding protein-5 for acid labile subunit
134. Plasminogen binds the heparin binding domain of insulin-like growth factor binding protein-3
135. Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I
136. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth
137. Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: An alternative mechanism in the regulation of IGF action
138. Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity
139. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type I IGF receptor gene
140. Nuclear localization of insulin-like growth factor binding protein-3 in a lung cancer cell line
141. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells
142. Insulin-like growth factor binding protein-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells
143. Direct functional interactions between insulin-like growth factor binding protein-3 and retinoic acid X receptor regulate transcription, signaling and apoptosis
144. Nuclear import of insulin-like growth factor binding protein-3 and -5 is mediated by the importin B subunit
145. Effect of insulin-like growth factor binding protein-1 on integrin signaling and the induction of apoptosis in human breast cancer cells
146. Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes
147. Characterization of insulin-like growth factor binding protein-1 kinases from human hepatoma cells
148. The effect of phosphorylation by casein kinase on the activity of insulin-like growth factor binding protein-3
149. Phosphorylation of insulin-like growth factor binding proteins
150. Purified preparations of the amniotic fluid IGF binding protein contain multimeric forms that are biologically active
151. The role of insulin like growth factor binding proteins in controlling the expression of IGF actions
152. Tissue tranglutaminase facilitates the polymerization of insulin-like growth factor binding protein-1 and leads to loss of IGFBP-1's ability to inhibit IGF-I stimulated protein synthesis